Lucie Delfos
Promovendus
- Naam
- L. Delfos MSc
- Telefoon
- +31 71 527 2727
- l.delfos@lacdr.leidenuniv.nl
- ORCID iD
- 0000-0003-1018-191X
Promovendus
- Wiskunde en Natuurwetenschappen
- Leiden Academic Centre for Drug Research
- LACDR/Biopharmaceutics
- Depuydt M.A.C., Smit V., Schaftenaar F.H., Hemme E., Delfos L., Vlaswinkel F.D., Simpson C., Kovanen P.T., Slütter B.A., Kuiper J., Bot I. & Foks A.C. (2024), Aging promotes mast cell activation and antigen presenting capacity in atherosclerosis, Cardiovascular Research 120(Supplement 1): cvae088.201.
- Bot I., Delfos L., Hemme E., Bernabé Kleijn M.N.A., Santbrink P.J. van, Foks A.C., Kovanen P.T., Jouppila A. & Lassila R. (2024), Treatment with APAC, a dual antiplatelet anticoagulant heparin proteoglycan mimetic, limits early collar-induced carotid atherosclerotic plaque development in Apoe-/- mice, Atherosclerosis 397: 118567.
- Hemme E., Depuydt M.A.C., Delfos L., Kuiper J. & Bot I. (2023), Leukemia inhibitory factor receptor inhibition in atherosclerosis, Atherosclerosis 379: S36.
- Delfos L., Depuydt M.A.C., Foks A.C., Bernabe Kleijn M.N.A., Kuiper J., Chemaly M., Peace A., McGilligan V. & Bot I. (2023), NLRP3 inflammasome inhibition by the novel bispecific antibody inflamab inhibits atherosclerosis in apolipoprotein E-deficient mice, Atherosclerosis 379(Supplement 1): S2.
- Depuydt M.A.C., Schaftenaar F.H., Prange H.H.M., Boltjes A., Hemme E., Delfos L., Mol J. de, Jong M.J.M. de, Bernabé Kleijn M.N.A., Peeters J.A.H.M., Goncalves L., Wezel A., Smeets H.J., Borst G.J. de, Foks A.C., Pasterkamp G., Winther M.P.J. de, Kuiper J., Bot I. & Slütter B. (2023), Single-cell T cell receptor sequencing of paired human atherosclerotic plaques and blood reveals autoimmune-like features of expanded effector T cells, Nature Cardiovascular Research 2: 112-125.
- Skenteris N.T., Hemme E., Delfos L., Karadimou G., Karlöf E., Lengquist M., Kronqvist M., Zhang X., Maegdefessel L., Schurgers L.J., Arnardottir H., Biessen E.A.L. & Bot I. Matic L. (2023), Mast cells participate in smooth muscle cell reprogramming and atherosclerotic plaque calcification, Vascular Pharmacology 150: 107167.
- Hemme E., Delfos L., Depuydt M.A.C., Bernabé Kleijn M.N.A., Schaftenaar F.H., Foks A.C., Kuiper J. & Bot I. (2022), Brutons tyrosine kinase inhibition to suppress mast cell activation in atherosclerosis, Cardiovascular Research 118(Supplement_1): cvac066.227.
- Bot I., Delfos L., Hemme E., Kovanen P.T., Jouppila A. & Lassila R. (2022), APAC treatment limits collar-induced carotid atherosclerotic plaque development in apoE-/- mice, Cardiovascular Research 118(Supplement_1): cvac066.183.
- Depuydt M.A.C., Vlaswinkel F.D., Hemme E., Delfos L., Bernabe Kleijn M.N.A., Santbrink P.J. van, Foks A.C., Slütter B., Kuiper J. & Bot I. (2022), Blockade of the BLT1-LTB4 axis does not affect mast cell migration towards advanced atherosclerotic lesions in LDLr-/- mice, Scientific Reports 12(1): 18362.
- Postel R.J., Smit V., De Mol J., Bernabé Kleijn M.N.A., De Jong M.J.M., Delfos L., Hemme E., Depuydt M.A.C., Bot I., Kuiper J. & Foks A.C. (2022), IL-21R blockade reduces atherosclerosis development in LDLR-/- mice, Atherosclerosis 355: 23.